Cagrilintide

Cagrilintide is a 32-residue analog of human amylin, a pancreatic islet peptide co-secreted with insulin. It carries an intramolecular disulfide bridge between the cysteines near the N-terminus and a C-terminal amide, both of which the native sequence also has and both of which are required for receptor engagement.

The central engineering problem this molecule addresses is aggregation. Native human amylin is strongly amyloidogenic and readily forms insoluble fibrils in solution, which makes the unmodified sequence impractical as a research reagent. Substitutions in the aggregation-prone central region suppress that behaviour, and a C20 fatty diacid conjugated through a spacer drives albumin binding. Its targets are the amylin receptors, which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins.

In-vitro characterisation centres on cAMP accumulation in cell lines co-expressing the calcitonin receptor with each of the three receptor activity-modifying proteins, since selectivity across those heterodimer combinations is the meaningful pharmacological description for an amylin analog rather than a single affinity figure.

A second and unusual strand of the literature concerns fibrillation itself. Thioflavin T fluorescence assays and transmission electron microscopy are used to compare aggregation kinetics against native amylin, and those measurements are as central to characterising this molecule as receptor binding is. Animal-model work has examined satiation-related signalling at hindbrain amylin receptor populations.

This sequence contains cysteine, which changes what lot release has to establish. Beyond reversed-phase HPLC purity and mass spectrometry identity, the disulfide bridge must be confirmed as correctly formed, because a scrambled or reduced variant has a mass differing by only two daltons from the intended molecule and is readily missed on a routine mass check.

Peptide mapping under non-reducing conditions is the method that resolves this, and the C-terminal amide requires separate confirmation since the free-acid form is a common and inactive by-product. Size-exclusion chromatography is worth running on any amylin analog to detect soluble aggregate, which will not appear on a reversed-phase purity assay at all.